Abstract:Background The retina is considered a unique window to systemic health, but their biological link remains unknown. Methods A total of 93,838 UK Biobank participants with metabolomics data were included in the study. Plasma metabolites associated with GCIPLT were identified in 7,824 participants who also underwent retinal optical coherence tomography; prospective associations of GCIPLT-associated metabolites with 12-year risk of mortality and major age-related diseases were assessed in 86,014 participants. The primary outcomes included all- and specific-cause mortality. The secondary outcomes included incident type 2 diabetes mellitus (T2DM), obstructive sleep apnea/hypopnea syndrome (OSAHS), myocardial infarction (MI), heart failure, ischemic stroke, and dementia. C-statistics and net reclassification indexes (NRIs) were calculated to evaluate the added predictive value of GCIPLT metabolites. Calibration was assessed using calibration plots. Findings Sixteen metabolomic signatures were associated with GCIPLT (P< 0.009 [Bonferroni-corrected threshold]), and most were associated with the future risk of mortality and age-related diseases. The constructed meta-GCIPLT scores distinguished well between patients with high and low risks of mortality and morbidity, showing predictive values higher than or comparable to those of traditional risk factors (C-statistics: 0.780[0.771-0.788], T2DM; 0.725[0.707-0.743], OSAHS; 0.711[0.695-0.726], MI; 0.685[0.662-0.707], cardiovascular mortality; 0.657[0.640-0.674], heart failure; 0.638[0.636-0.660], other mortality; 0.630[0.618-0.642], all-cause mortality; 0.620[0.598-0.643], dementia; 0.614[0.593-0.634], stroke; and 0.601[0.585-0.617], cancer mortality). The NRIs confirmed the inclusion of GCIPLT metabolomic signatures to the models based on traditional risk factors resulted in significant improvements in model performance (5.18%, T2DM [P=3.86E-11]; 4.43%, dementia [P=0.003]; 4.20%, cardiovascular mortality [P=6.04E-04]; 3.73%, MI [P=1.72E-07]; 2.93%, OSAHS [P=3.13E-05]; 2.39%, all-cause mortality [P=3.89E-05]; 2.33%, stroke [P=0.049]; 2.09%, cancer mortality [P=0.039]; and 1.59%, heart failure [P=2.72E-083.07E-04]). Calibration plots showed excellent calibration between predicted risk and actual incidence in the new models. Interpretation GCIPLT-associated plasma metabolites captured the residual risk for mortality and major systemic diseases not quantified by traditional risk factors in the general population. Incorporating GCIPLT metabolomic signatures into prediction models may assist in screening for future risks of these health outcomes. Funding National Natural Science Foundation (China). Evidence before this study Recent studies have recognized that retinal measurements can indicate an accelerated risk of aging and multiple systemic diseases preceding clinical symptoms and signs. Despite these insights, it remains unknown how retinal alterations are biologically linked to systemic health. Added value of this study Using the UK Biobank, we identified ganglion cell–inner plexiform layer thickness (GCIPLT) metabolomic signatures, and revealed their association with the risk of all- and specific-cause mortality and six age related diseases: type 2 diabetes, dementia, stroke, myocardial infarction, heart failure, and obstructive sleep apnea/hypopnea syndrome. The meta-GCIPLT score significantly improved the discriminative power of the predictive models for theses health outcomes based on conventional risk factors. Implications of all the available evidence GCIPLT-associated plasma metabolites have the potential to capture the residual risk of systemic diseases and mortality not quantified by traditional risk factors. Incorporating GCIPLT metabolomic signatures into prediction models may assist in screening for future risks of these health outcomes. Since metabolism is a modifiable risk factor that can be treated medically, the future holds promise for the development of new strategies that reverse or interrupt the onset of these diseases by modifying metabolic factors. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was funded by the National Natural Science Foundation of China (82000901), the Guangzhou Science & Technology Plan of Guangdong Pearl River Talents Program (202102010162), the Fundamental Research Funds of the State Key Laboratory of Ophthalmology (303060202400362). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used (or will use) ONLY openly available human data from UK Biobank via data access procedures (<http://www.ukbiobank.ac.uk>). Permission to use the UK Biobank Resource was obtained via material transfer agreement as part of Application 62443, 62489, 62491 and 62525. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors. * OCT : optical coherence tomography GCIPL : ganglion cell-inner plexiform layer RNFL : retinal nerve fiber layer GCIPLT : GCIPL thickness RGC : retinal ganglion cell OSAHS : obstructive sleep apnea/hypopnea syndrome MI : myocardial infarction NHS : National Health Service NMR : nuclear magnetic resonance BMI : body mass index WHR : waist-to-hip ratio IOP : intraocular pressure CI : confidence interval HDL : high-density lipoprotein apoE : apolipoprotein E apoA1 : apolipoprotein A1 FA : fatty acid, SE : standard error apoB : apolipoprotein B; TG : triglyceride VLDL : very low-density lipoprotein IH : intermittent hypoxia Aβ : amyloid β

The Association of Retinal age gap with metabolic syndrome and inflammation

Clinical Usefulness Of Metabolic Risk Factors To Identify Young Asymptomatic Women Adults With Subclinical Atherosclerosis: A Cross-Sectional Study

Association of Retinal Age Gap With Arterial Stiffness and Incident Cardiovascular Disease.

Metabolomic Signature of Retinal Ageing, Polygenetic Susceptibility, and Major Health Outcomes

Retinal Age as a Predictive Biomarker for Mortality Risk

Retinal age gap as a predictive biomarker for mortality risk

Proteome-wide Mendelian randomization study implicates inflammaging biomarkers in retinal vasculature, cardiometabolic diseases and longevity

Association of retinal age gap with chronic kidney disease and subsequent cardiovascular disease sequelae: a cross-sectional and longitudinal study from the UK Biobank

Glycemic status and its association with retinal age gap: Insights from the UK biobank study

Ageing Biomarkers Derived From Retinal Imaging: A Scoping Review

Retinal age gap as a predictive biomarker of stroke risk

Estimating biological age from retinal imaging: a scoping review

Identification of the Metabolic Signature of Aging Retina

Age difference in the connection between systemic inflammatory response and metabolic syndrome

Retinal Age Gap As a Predictive Biomarker of Future Risk of Parkinson's Disease

Retinal Fractal Dimension Is a Potential Biomarker for Systemic Health—Evidence From a Mixed-Age, Primary-Care Population

Retinal age gap as a predictive biomarker of future risk of Parkinson’s disease

Association of Metabolic Syndrome with Macular Thickness and Volume in Older Adults: A Population-Based Optical Coherence Tomography Study

Genomic Determinants of Biological Age Estimated By Deep Learning Applied to Retinal Images

A lipidomic based metabolic age score captures cardiometabolic risk independent of chronological age

Metabolic signature of the ganglion cell–inner plexiform layer thickness and the risks of mortality and morbidity: a population-based study in UK Biobank